RussianPatents.com

Method of determining antibacterial activity of chitosan. RU patent 2450022.

FIELD: chemistry.

SUBSTANCE: disclosed is a method of determining antibacterial properties of chitosan by estimating its minimum bacteriostatic and/or bactericidal concentration. Complex buffer solutions based on three organic acids MES, ACES and TES with different pH values are prepared. The ready buffer solutions are poured into a vessel. Double dilutions of chitosan are then prepared in vessels with the buffer solutions. Aliquots of a bacterial suspension in a fluid medium are added to the chitosan solutions in the buffer. The solutions are incubated for 24 hours at temperature which is optimum for bacterial growth. The minimum bacteriostatic and/or minimum bactericidal concentration of chitosan is then determined after incubation by determining growth of the culture or a drop in the number of living cells, respectively.

EFFECT: invention enables to determine antibacterial properties of chitosan in a wide pH range from 5,50 to 8,00 without the need to use buffers of different chemical composition.

5 dwg, 2 ex

IPC classes for russian patent Method of determining antibacterial activity of chitosan. RU patent 2450022. (RU 2450022):

C08B37/08 - Chitin; Chondroitin sulfate; Hyaluronic acid; Derivatives thereof

A61K31/722 -

Another patents in same IPC classes:

Method for preparing boron-containing hyaluronic acid / 2445978
Invention refers to a method for preparing sodium salt of hyaluronic acid modified by boron compounds with no fluid medium added. The method consists in the fact that powdered sodium salt of hyaluronic acid together with a modifying agent and mixed modifying agents is pre-homogenised in a mixer at temperature ranging within 20° to 50°C; thereafter the prepared homogenous powder mixture is simultaneously exposed to pressure and shearing deformation in a mechanochemical reactor at temperature ranging within 20° to 50°C and pressure 5-1000 MPa.

Method for producing chitosan oligomers / 2445101
Invention refers to medicine, more specifically to producing chitosan oligomers possessing biological activity and applicable in food industry and medicine. In a method for producing chitosan oligomers, a chitosan solution is taken in the concentration of 0.025-0.075% (weight/volume) and exposed to low-frequency ultrasound of the intensity of 92-460 Wt/cm2 for 5-30 minutes.

Method of producing d(+) glucosamine hydrochloride / 2440362
Method involves preliminary acetylation of chitin with acetic anhydride, washing and drying the acetylated chitin in order to reduce degree of deacetylation thereof and, as a result, increase output of the desired product - D(+)-glucosamine hydrochloride when obtaining said product through hydrolysis of acetylated chitin with concentrated hydrochloric acid while heating, followed by evaporation, crystallisation, separation, washing and drying the desired product.

Chitosan chromate, synthesis method thereof and energy-intensive composition containing said chitosan chromate / 2439081
Method of producing chitosan chromate involves reaction of soluble chitosan salts with metal chromates in ratio of 2 moles of the chitosan cation to 1 mole of chromate anion or with metal bichromates in ratio of 4 moles of the chitosan cation to 1 mole of the bichromate anion. The solid chitosan chromate residue formed is then separated and dried at temperature not higher than 150°C. The invention discloses an energy-intensive composition based on chitosan dodecahydro-closo-dodecaborate containing an effective amount of chitosan chromate. The quantitative ratio in the energy-intensive composition is by the required combustion mode: the higher the content of chitosan chromate, the higher the activity of the composition.

Method of determining degree of deacetylation of chitosan / 2436798
Method involves taking a certain weighed amount of chitosanium chromate which is first purified from extraneous impurities and reduced to constant weight. The weighed amount is then turned into a stable weighted form through thermal treatment on air at temperature 800-900°C to form chromium oxide Cr2O3. The weight of the formed chromium oxide is then determined. Content of chromic acid in the initial weighed amount of chitosanium chromate is then calculated from the weight of chromium oxide. The degree of deacetylation of chitosan is calculated using defined formulae.

Method of extracting and stabilising low-molecular aminoglycans from eggshell wastes / 2435786
Invention relates to a method of extracting and stabilising ultra low-molecular aminoglycans from eggshell wastes. Aminoglycan extract is used to produce cosmetic creams with skin moisturising and anti-wrinkle properties. The method of extracting low-molecular aminoglycan compound of formula I from a natural source of eggshell wastes, which consists of alternating glucuronic acid and N-acetylglucosamine units, where M can be one or more of Na, Ca, K, Mg; and n is a whole number from 20 to 40, involves the following steps: (a) preparing eggshell wastes for extraction of embryonic low-molecular aminoglycan compound of formula I using a polar organic solvent in water, (b) extracting low-molecular aminoglycan compound of formula I in form of a water-soluble salt, for which the eggshell from step (a) is vigorously shaken with aqueous polar salt solution at 10°C - 35°C for 6-12 hours, then filtered or centrifuged in order to collect an aqueous layer containing a dissolved aminoglycan compound of formula I; (c) extracting a purified low-molecular aminoglycan compound of formula I by forming a gel from an aqueous mixture of salts using a polar organic solvent, for which the solution from step (b) is successively and step-by-step mixed with an organic solvent mixed with water while gently stirring and then cooled to maintain temperature from 20°C to 25°C, and the formed gel is left for 2-24 hours for complete precipitation, then filtered or centrifuged in order to extract a semidry aminoglycan compound of formula I; (d) the extracted aminoglycan compound of formula I from step (c) is stabilised via gradual addition of organic oils to the semidry gel to form aminoglycan compound of formula I. In order to prepare a composition having anti-wrinkle properties, at least one pharmaceutically acceptable filler is added to the stabilised aminoglycan compound of formula I obtained at step (d).

Method and apparatus for treating fermented wastes and producing chitin containing biomass / 2430929
Method involves feeding wastes to be treated into artificial containers, biotreatement, tapping the filtrate and removing the obtained biomass. Biotreatement is carried out by culturing hoverfly larvae from the freshly laid eggs phase to the pupation phase in the fermented wastes to be treated, placed in artificial meshed containers the bottom and walls of which are covered with filter cloth. The apparatus has artificial containers, devices for feeding the wastes to be treated, outputting the filtrate and collecting the biomass. The artificial containers have a meshed bottom and walls covered with filter cloth.

Method of producing nanoparticles of low-molecular chitosan / 2428432
Method of producing nanoparticles of low-molecular chitosan involves preparing a solution of pre-purified low-molecular chitosan in filtered 1-2 wt % aqueous acetic acid, adding solutions of hydroxides of alkali metals or ammonia for 2 hours, dispersing the system using a mechanical mixer at a rate of 200-300 rpm at temperature 20°C to pH 6.9-7.0. Further, the dispersion is centrifuged at 10000 rpm. The obtained solid residue is redispersed in bidistillate while mechanically mixing at a rate of 200-300 rpm at temperature 20°C.

Method of producing low-molecular chitosan in salt-free medium via enzymatic polymerisation / 2425844
Starting high-molecular chitosan is dissolved in acid solution. The chitosan dissolved in the acid is then precipitated by adding alkali solution. The re-precipitated high-molecular chitosan is washed from the formed salt and excess alkali using a coarse-porous filter. The re-precipitated chitosan is dissolved in acid solution until achieving pH 5.5. An enzyme preparation is then added and hydrolysis is carried out. The reaction is stopped after formation of low-molecular chitosan.

Compositions of partially deacetylated chitin derivatives / 2421467
Method for the recovery of high-purity and completely soluble partially deacetylated chitin polymer of deacetylation degree (DD) 30-60 % involves the stages: neutralisation of partially deacetylated chitin; dissolution of partially deacetylated chitin in an acid; removal of undissolved particles by sequential filtration stages; pH reduction of the solution to 8 and more; precipitation of completely dissolved and purified partially deacetylated chitin by temperature rise and salt addition where the precipitate is removed and rinsed after precipitation by filtration or centrifugation and where rinsing water and deposit temperature is 40°C and higher. Also the invention refers to a neogenesis composition containing therapeutically active N-acetylglucosamine (A) and glucosamine (D) chitooligomers where the composition contains heterochitooligomers which shall meet the following criteria: said oligomers have a chain length in the range 5-20 monomer residues; each oligomer chain can have two residues of N-acetyl-D-glucosamine (AA) on any or both ends of the oligomer chain, the remained inside of the oligomer has a maximum number of the residues A; the sequence of said inside of the chain is such that the N-acetyl-D-glucosamine residue (A) does not adjoin to the other N-acetyl-D-glucosamine (A) residue (such as, e.g. AA).

Cationic latex as carrier for bioactive ingredients and methods of obtaining and using said latex / 2444541
Bioactive cationic polymer latex contains a latex polymer, at least one bioactive component at least partially encapsulated by a latex polymer and, optionally, at least one volumetric component contained in the latex polymer. The latex is obtained through emulsion polymerisation of monomers to form polymer latex in the presence of at least one bioactive component. The latex is a product of polymerisation of at least a first ethylenically unsaturated monomer and at least a second ethylenically unsaturated monomer, which is cationic or a cation precursor. The bioactive component used can be antibacterial and antifungal agents. The invention also describes methods of obtaining and using bioactive cationic polymer latex.

Preparation accelerating wound healing / 2440122
Invention refers to medicine and concerns a preparation accelerating wound healing and exhibiting antimicrobial activity. The preparation presents a low-molecular chitosan (LMC) solution of molecular weight 5-72 kDa, a degree of deacetylation 20-89% in hydrogel containing methyl cellulose (MC-100) and water. The preparation can additionally contain glycerine and Nipagin in the following proportions, g: LMC - 0.05-2.0, MC-100 - 1.0-3.0, glycerine - 10.0-20.0, Nipagin - 0.1-0.3, water to 100.0.

Method for preparing water-soluble chitosan para-aminosalicylate / 2440111
Invention refers to medicine, namely to phthisiology and pharmaceutical industry. A method for preparing a water-soluble chitosan para-aminosalicylate consists in preparing an aqueous solution of para-aminosalicylic acid (2.8 wt %) at temperature 90°C, adding low-molecular chitosan (low molecular weight 3.9 and 30 kDa) in amount 2.8 wt % in mixing with a mechanical mixer, dispersing a reaction mixture at temperature 85°C for 40 minutes. After termination of the process, the reaction mixture is vacuumised; a solid residue is dried in vacuum at temperature 30°C.

Complex antiviral medication for external application in treatment of herpes virus infections / 2438697
Invention relates to medicine, namely, to virology, pharmacy, and is intended for treatment of herpetic infections For this purpose applied is complex antiviral medication for external application, which contains (in wt %) recombinant interferon α - 2b (40-50) 106 IU, hyaluronic acid - 0.5-1.0, chitosan succinate - 1.0-2.0, licorice root extract - 0.2-0.5, zinc oxide - 0.8-2.0, lidocaine or dicaine - 0.8-1.0, polyethylenoxide-1500 - 5.0-7.0, anhydrous lanolin - 22.0-27.0, medical vaseline - 35.0-40.0, glycerin - 5.0-8.0, distillated water to 100,0 Medication ensures prolonged anti-inflammatory, anesthetic, wound-healing impact on herpetic affection of mucous membranes and skin, including genital herpes, opthalmo-herpes and shingles.

Method of obtaining hydrogel of medicinal purpose (versions) / 2432954
Invention relates to pharmaceutical industry, namely, to obtaining form-stable hydrogel matrices, intended for addressed prolonged release of medications, demonstrating regenerating, wound-healing, anti-inflammatory immunostimulating or antioxidant activity. Obtaining of form-stable hydrogels based on sodium alginate and chitosan with addition of salts of diacids can be realised by interaction of initial substances in two versions - by introduction into volume of water solution of sodium algenate with small content of chitosan of colloidal solutions of insoluble salts of diacids (method of reinforcement) or in mixing water solutions of sodium algenate and chitosan with superficial processing with soluble salts of diacids (method of submerging).

Method of abatement of heartburn and gastroesophageal reflux disease (gerd) by means of special polysaccharides / 2432167
Invention refers to pharmaceutical industry, particularly, to a preparation for treating heartburn and/or gastroesophageal reflux disease. A pharmaceutical preparation for treating heartburn and/or gastroesophageal reflux disease containing an effective amount of water-soluble branched or linear polysaccharide which represents galactomannan made of fenugreek seeds. A method of treating heartburn and/or gastroesophageal reflux disease in a human. Application of fenugreek seed galactomannan for producing the drug for treating heartburn and/or gastroesophageal reflux disease. Application of fenugreek seed galactomannan for producing the drug for delay or prevention of onset and development of acid-peptic disorders or the diseases caused by the other injures of gastric mucosa and epithelium. Application of fenugreek seed galactomannan for producing the drug for abatement of pregnancy-related temporary acid reflux.

Method for evaluating effectiveness of chitosan film coatings by microorganism sensitivity and burn wound depth during various periods of burn diseases / 2430154
Evaluating effectiveness of film coatings in burn wound repair is enabled by determining microorganism sensitivity to chitosan film coatings. An effect of the coating on the wound microflora is evaluated by incubation of the wound microflora and the coating on a nutrient agar medium to be thereafter analysed for microflora sensitivity to the coating by the absence of bacterial growth. The incubation process is performed at 37°C for 24 hours. Microorganism sensitivity is evaluated consistently during each period of burn disease, thereafter the coating is replaced by that one considered being the most effective.

"tablets for mind" medication / 2429001
Medication contains the following components per tablet weight of 350 mg: water-soluble chitosan 25.0; powder of Scutellaria baicalensis roots 15.0; powder of Schizonepeta multifida herb 50.0; powder of ginger root 35.0; powder of Rhodiola rosea root 10.0; powder of herb of Astragalus membranaceus 25.0; powder of root of Maral root 30.0; powder of herb of Phlojodicarpus villosus 40.0; powder of Bacora monnieri herb 20.0; chaga powder - the remaining part.

Laser-beam bio-tissue welding technique / 2425700
Laser-beam welding is conducted with using a biological solder which represents a dispersion of binding agent in the form of an aqueous composite of proteins and/or biocompatible polymers additionally containing carbon nanotubes and surface-active substances.

Composition of nail vanish / 2245715
The present innovation deals with, a) at least, one fungicide substance and b) at least, one water-soluble film-forming substance, where b)-component is chitosan derivative chosen out of hydroxyalkyl chitosans and carboxyalkyl chitosans; nail vanish that includes the above-mentioned composition, and nail vanish that includes, at least, one water-soluble film-forming substance chosen out of hydroxyalkyl chitosans and carboxyalkyl chitosans. The suggested nail vanish is of high fungicide action and is free of multiple dermatological and esthetic disadvantages.